Figure 2. Genomic amplifications of PHGDH in cancer and association of PHGDH expression with aggressive breast cancer markers.

a, PHGDH vicinity copy number (CN) data for melanoma (left, n=111) and breast cancer (BC, right, n=243) samples. Coloured bar indicates degree of CN loss (blue) or gain (red). Samples sorted by CN at PHGDH locus (dotted lines). Graphs at left of CN data shows amplification significance (−log₁₀(q-value), ~0.60 is the significance threshold for amplification). b, Representative PHGDH gene expression data for indicated BC groups. Whiskers indicate 91^st and 9^th percentile. c, Table reports numbers of human BC samples with “weak”, “moderate”, or “strong” PHGDH staining from BC subgroups indicated. Representative staining intensities shown in images. Asterisk indicates p<0.0001 comparing ER-positive versus ER-negative classes (Fisher’s exact test). d–f, PHGDH protein levels are shown for (d) PHGDH amplified versus non-amplified (annotated with “+” or “−“), (e) PHGDH non-amplified, over-expressing, and (f) MCF10A derived cell lines. Values below PHGDH immunoblots are normalized immunoflourescent quantification (LI-COR) of PHGDH levels relative to actin control and MCF10A and MCF7.